Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper.
Aldehyde Oxidase
/ metabolism
Algorithms
Animals
Antineoplastic Agents
/ adverse effects
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Colitis
/ diagnosis
Cytochrome P-450 CYP3A
/ metabolism
Diarrhea
/ diagnosis
Disease Management
Drug Interactions
Humans
Leukemia, Lymphocytic, Chronic, B-Cell
/ diagnosis
Lymphoma, Follicular
/ diagnosis
Purines
/ adverse effects
Quinazolinones
/ adverse effects
adverse events
chronic lymphocytic leukemia
follicular lymphoma
idelalisib
Journal
Hematological oncology
ISSN: 1099-1069
Titre abrégé: Hematol Oncol
Pays: England
ID NLM: 8307268
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
26
06
2018
revised:
09
07
2018
accepted:
10
07
2018
pubmed:
7
9
2018
medline:
6
3
2019
entrez:
7
9
2018
Statut:
ppublish
Résumé
The introduction of new therapeutic agents in chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL), including the new kinase inhibitor idelalisib, has changed the therapeutic landscape of these diseases. However, the use of idelalisib is associated with a peculiar profile of side effects, which require an optimization of the current approach to prophylaxis and supportive treatment. Moving from the recognition that the abovementioned issue represents an unmet need in CLL and FL, a multidisciplinary panel of experts was convened to produce a consensus document aiming to provide practical recommendations for the management of the side effects during idelalisib therapy for CLL and FL. The present publication represents a consensus document from a series of meetings held during 2017. The Panel generated clinical key questions using the criterion of clinical relevance through a Delphi process and explored 4 domains, ie, diarrhea/colitis, transaminitis, pneumonitis, and infectious complications. Using the consensus method, the Panel was able to shape recommendations which may assist hematologist to minimize adverse events and guarantee adherence to treatment in patients with CLL and FL candidate to receive idelalisib.
Identifiants
pubmed: 30187496
doi: 10.1002/hon.2540
pmc: PMC6585802
doi:
Substances chimiques
Antineoplastic Agents
0
Purines
0
Quinazolinones
0
Cytochrome P-450 CYP3A
EC 1.14.14.1
Aldehyde Oxidase
EC 1.2.3.1
idelalisib
YG57I8T5M0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3-14Informations de copyright
© 2018 The Authors Hematological Oncology Published by John Wiley & Sons Ltd.
Références
Blood. 2016 Jul 21;128(3):331-6
pubmed: 27252232
JAMA. 2016 Jun 14;315(22):2435-41
pubmed: 27179847
Nature. 2017 Feb 23;542(7642):489-493
pubmed: 28199309
Sarcoidosis Vasc Diffuse Lung Dis. 2008 Sep;25(1):36-45
pubmed: 19070259
Hematology Am Soc Hematol Educ Program. 2012;2012:88-96
pubmed: 23233565
Hematol Oncol. 2018 Oct;36(4):624-632
pubmed: 29512173
Leuk Lymphoma. 2015;56(10):2779-86
pubmed: 25726955
Hepatology. 2018 Jan;67(1):48-55
pubmed: 28714143
J Antimicrob Chemother. 2016 Sep;71(9):2397-404
pubmed: 27550992
Blood. 2017 Jun 1;129(22):3037-3039
pubmed: 28325864
Nat Rev Drug Discov. 2012 Oct;11(10):751-61
pubmed: 22935759
Blood. 2016 Apr 28;127(17):2055-63
pubmed: 26989204
Blood. 2014 May 29;123(22):3398-405
pubmed: 24615778
Pharmacoepidemiol Drug Saf. 2014 May;23(5):489-97
pubmed: 24616171
BMJ Case Rep. 2016 Aug 02;2016:
pubmed: 27485880
Blood. 2016 Jul 14;128(2):195-203
pubmed: 27247136
Am J Surg Pathol. 2015 Dec;39(12):1653-60
pubmed: 26426383
Eur Respir J. 2016 Apr;47(4):1280-3
pubmed: 26917607
Chest. 2017 Aug;152(2):271-281
pubmed: 28499515
Hematol Oncol. 2019 Feb;37(1):3-14
pubmed: 30187496
Chest. 2017 Jun;151(6):1356-1374
pubmed: 28212835
Transplantation. 2013 Aug 27;96(4):333-60
pubmed: 23896556
Gastroenterology. 2015 Jan;148(1):215-9; quiz e16-7
pubmed: 25447850
Blood. 2015 Dec 17;126(25):2686-94
pubmed: 26472751
Clin Pharmacokinet. 2016 Jan;55(1):33-45
pubmed: 26242379
Blood. 2018 Feb 22;131(8):877-887
pubmed: 29191916
Clin Lymphoma Myeloma. 2006 Sep;7(2):125-30
pubmed: 17026823
Ann Oncol. 2017 May 1;28(5):1050-1056
pubmed: 28453705
J Antimicrob Chemother. 2016 Sep;71(9):2379-85
pubmed: 27550990
Curr Med Mycol. 2015 Mar;1(1):42-48
pubmed: 28680980
Lancet Oncol. 2017 Mar;18(3):297-311
pubmed: 28139405
Eur Respir J. 2017 Aug 24;50(2):
pubmed: 28838977
Cancer Chemother Pharmacol. 2015 Dec;76(6):1133-41
pubmed: 26526983
AAPS J. 2006 Feb 03;8(1):E48-54
pubmed: 16584133
Am J Surg Pathol. 2015 Dec;39(12):1661-7
pubmed: 26448188
Blood. 2011 Jan 13;117(2):591-4
pubmed: 20959606
N Engl J Med. 2014 Mar 13;370(11):1008-18
pubmed: 24450858
Blood. 2015 May 21;125(21):3357-9
pubmed: 25999447
J Adv Nurs. 1994 Jan;19(1):180-6
pubmed: 8138622
Gastroenterology. 2010 Nov;139(5):1642-53, 1653.e1-6
pubmed: 20637203
Hepatology. 2018 Jan;67(1):36-47
pubmed: 28653760
Am J Respir Crit Care Med. 2012 May 1;185(9):1004-14
pubmed: 22550210
Haematologica. 2016 Dec;101(12):1563-1572
pubmed: 27756834
Intern Med J. 2014 Dec;44(12b):1350-63
pubmed: 25482745
N Engl J Med. 2014 Mar 13;370(11):997-1007
pubmed: 24450857
Crit Care. 2017 Sep 12;21(1):240
pubmed: 28899408
Chest. 2017 Dec;152(6):1151-1158
pubmed: 28823812
J Clin Pharmacol. 2015 Aug;55(8):944-52
pubmed: 25821156
Leukemia. 2020 Dec;34(12):3404-3407
pubmed: 32655145
Blood. 2014 May 29;123(22):3390-7
pubmed: 24615777
Gastroenterology. 2017 May;152(6):1297-1309
pubmed: 28219691
Respiration. 2004 Mar-Apr;71(2):107-19
pubmed: 15031564
Blood. 2010 Sep 23;116(12):2078-88
pubmed: 20522708
Ann Oncol. 2017 Jul 1;28(suppl_4):iv149-iv152
pubmed: 28881925
Haematologica. 2017 Oct;102(10):1629-1639
pubmed: 28775119
Lancet Haematol. 2017 Mar;4(3):e114-e126
pubmed: 28257752
Blood. 2014 May 29;123(22):3406-13
pubmed: 24615776
Rev Prat. 2014 Sep;64(7):951-6
pubmed: 25362778
J Clin Pharmacol. 2015 Aug;55(8):909-19
pubmed: 25760671
Expert Opin Investig Drugs. 2017 Nov;26(11):1267-1279
pubmed: 28945111
Pathologica. 2012 Apr;104(2):65-9
pubmed: 22953502
Br J Haematol. 2018 Mar;180(5):666-679
pubmed: 29318593
Oncology (Williston Park). 2017 Nov 15;31(11):821-8
pubmed: 29179250